Background: This study aims to evaluate the influence of nanoparticle size on the in vitro percutaneous penetration and retention and in vivo antiinflammatory efficacy of percutaneously delivered non-steroidal anti-inflammatory drugs. Methods: Indomethacin, ketoprofen and piroxicam were incorporated into nanoparticles. The nanoparticles, or the bulk-drug equivalents, were suspended in a hydrophilic ointment and compared for their ability to facilitate percutaneous drug penetration and retention in vitro. The formulations were applied cutaneously in a carrageenan-induced footpad inflammation model (acute inflammation) and an adjuvant-induced arthritis model (chronic inflammation) in rats and were assessed for their anti-inflammatory efficacy and potency.
Introduction
Nanotechnology has been described as a field aimed at creating materials with new functions and beneficial characteristics through the control of material structure/sequence at the nanometer level. 1, 2 Following advances in nanotechnology, it is now becoming possible to create drug delivery systems (DDSs) using nanoparticles or microparticles as drug carriers. Percutaneous drug delivery is often used as a route of administration for low-molecular-weight drugs. For example, a percutaneous route has been adopted for the administration of non-steroidal anti-inflammatory drugs (NSAIDs) to avoid the limitations of oral administration, such as gastrointestinal symptoms and renal impairment. 3 The skin is the largest organ in the human body. If certain chemicals are applied to the skin, the active ingredient can penetrate through the skin barrier and become distributed throughout the whole body via the intradermal capillaries. However, the skin also possesses a barrier mechanism to prevent the invasion of various materials into the body. 4, 5 For this reason, the penetration of materials across the skin is generally quite low, compared with penetration Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.across other tissues. The skin is composed of the epidermis (including the horny layer), the dermis, and subcutaneous tissue. Accessory structures in the skin, such as sweat glands, are also present, and span the epidermis and the dermis. Of these skin components, the horny layer has the highest barrier function. Therefore, the effective passage of drugs through the horny layer is an issue of particular focus in percutaneous drug delivery. 6e10 NSAIDs are widely used in the clinic because of their excellent anti-inflammatory and analgesic action. 11 However, oral-dose NSAIDs are associated with adverse systemic reactions, such as gastrointestinal symptoms and renal impairment. For this reason, percutaneously absorbable forms of NSAIDs are often used when dealing with local inflammatory diseases, making locally and percutaneously absorbable drug formulations important research targets. To improve skin penetration, various penetration-promoting agents 12,13 and particle sizes 14 have been studied, and different formulations such as liposomes, 15 gels, 16e19 ointments and creams 20, 21 have been investigated and utilized. The application of nanoparticles to the skin reportedly elevates drug penetration across the skin barrier. Nanoparticles are therefore expected to provide a means of improving drug penetration through the skin, and local DDSs using nanoparticles have the potential for extensive clinical use. However, differences in particle size can affect nanoparticle skin uptake, retention time during circulation, and the potential for adherence and degradation. Keeping these points in mind, we explored the potential of nanoparticles and microparticles as percutaneous drug carriers by preparing fine particles containing NSAIDs using a planetary centrifugal mixer and evaluating their skin penetration and safety. 22 In addition, the anti-inflammatory activity of the NSAID particles was evaluated in animal models of acute and chronic inflammation.
Methods

Materials and reagents
Indomethacin (IMC), ketoprofen (KET), piroxicam (PXC) and diclofenac sodium were purchased from Nacalai Tesque, Inc (Kyoto, Japan). Other reagents used were commercial grade.
Preparation of fine NSAIDs particles
NSAIDs were incorporated into fine particles by processing the drug, zirconia beads (2.5 g), and an aqueous polymer (hydroxypropyl cellulose SSL [HPC]) solution in a planetary centrifugal mixer (NP-100; THINKY Corporation; fitted with a À20
C freezer) at a rotation rate of 1700 rpm, a mixing time of 10 min, and a medium (zirconia ball) quantity (2.5 g). The particle size of the drug in the suspension was measured using a laser diffraction particle size distribution meter. The active ingredients (ai) used were IMC (IMCai), KET (KETai), and PXC (PXCai), and the fine-particle formulations of these drugs are expressed as IMCnano, KETnano, and PXCnano, respectively. 2 ) was harvested over time in a manner similar to that described in section 2.3.2.1. The harvested skin was cut into small pieces and combined with methanol for homogenization, followed by centrifugation for 30 min (15,000 Â g, 4 C). The supernatant was used as the test sample. The drug concentration in the test sample was measured using HPLC.
Test drug quantification method
The HPLC system used was an LC-10 System, Shimadzu Corporation (Kyoto, Japan). The concentration of NSAIDs was quantified in accordance with the Japanese Pharmacopoeia 16th edition.
Anti-inflammatory activity
Experimental animals
Male Wistar rats (5 weeks old) were purchased from Japan SLC, Inc. (Shizuoka, Japan). The rats were housed at 23 ± 2 C and 50 ± 3% humidity. The animals were divided into an untreated group, a drug-free vehicle treatment group, and a treatment group for each test drug (NSAIDai group and NSAIDnano group). The experiment was performed with the approval of the Animal Experiment Review Board of Kochi University and in accordance with the Guidelines for Animal Experiments of Kochi Medical School.
Test drugs
Using a method similar to that described in section 2.3.1, NSAID ointments were prepared at concentrations of 0.5, 1, and 3% and a dose-response test was then conducted using these ointments. To compare efficacies, ointments with the same concentrations as those of commercially available products (1 w/w% IMC, 3 w/w% KET, and 0.5 w/w% PXC) were used.
Carrageenan-induced footpad edema model 25e27
The left hindlimb pad volume was measured using a foot volume measuring device. A 0.5% carrageenan saline solution (0.1 mL) was injected subcutaneously into the left hindlimb pad, immediately followed by the application of each test drug ointment on gauze (2.0 cm Â 2.0 cm, 0.5 g) to the footpad and fixation with surgical tape. After addition of the test drugs, foot volume was measured over time and the percent increase in the footpad volume relative to the pre-injection volume, as well as the percentage of edema (edema coverage) and the AUC, were calculated. In addition, the effective dose 50 ([ED50], %) was calculated from the edema suppression rate (%) at 3 h after carrageenan treatment, and the edema suppression rate at each concentration.
Adjuvant-induced arthritis model 26,27
The right hindlimb volume was measured using the method described in section 2.4.3. Heat-treated nonviable Mycobacterium butyricum suspended in liquid paraffin (6 mg/mL; volume, 0.1 mL) was then injected intradermally into the hindlimb base. Fourteen days after adjuvant inoculation, the right hindlimb volume was measured; animals that were diagnosed as having definite arthritis (foot swelling rate of 80% or more) were selected and divided into groups so that the extent of right hindlimb swelling would be similar in each group. Beginning at 14 d post adjuvant inoculation, gauze bearing the test drug ointment (2.0 cm Â 2.0 cm, 0.5 g) was applied once daily to the skin over the right hindlimb joint for 7 consecutive days. The right hindlimb volume was measured at 1, 3, 5 and 7 d after the start of drug treatment. The magnitude of change in the right hindlimb volume was determined as the difference relative to the volume before adjuvant inoculation. In addition, the healing rate at 7 d after the start of drug treatment was calculated. The ED50 (%) at each concentration was calculated from the healing rate (%) at each concentration level at 7 d after the start of the test drug treatment. Healing rate (%) ¼ (V14-Vt7)/(V14-V0) Â 100.
Statistical analysis
The obtained values are shown as mean ± standard error. For all other measurements, a one-way ANOVA was used for dispersion analysis. Differences in the efficacy of each particle size preparation between two groups were tested using a t-test. Comparisons of each test drug treatment group with the untreated group or the drug-free vehicle treatment group were performed using Dunnet's multiple comparison.
Results
Formation of fine particles of NSAIDs
Fine particle formulations of IMC, KET and PXC were successfully created. However, diclofenac sodium could not be made into fine particles because it was soluble in the suspending agent. The particle sizes of the fine-particle NSAIDs are shown in Table 1 , and the distribution of the particle sizes is shown in Fig. 1 . The particle sizes of the active ingredient NSAIDs (IMCai, KETai, and PXCai) were in the micrometer range. Table 1 shows the stability data after crushing using the mixer. Particle size measured 14 d post crushing, was unchanged from that recorded immediately after crushing.
Skin penetration test
The influence of particle size on the cumulative skin penetration of each NSAID is shown in Fig. 2 . All of the NSAIDs showed a linear increase in the concentration of the penetrating drug. Compared with the active ingredient formulations, the nanoparticle preparations promoted penetration. A cumulative increase in the quantity of penetrated drug, compared with that of the respective active ingredients, was observed at 4, 2, and 4 h after the application of the IMC, KET and PXC nanoparticles, respectively. Skin penetration data are shown in Table 2 . IMCnano showed significantly higher penetration rate (Jc), drug penetration coefficient (Kp), and AUC (0 / 24) than IMCai. The penetration lag time (Tlag) was significantly shorter for IMCnano. Similar results were obtained for the KET and PXC preparations. Fig. 3 shows the influence of particle size on the concentration of each NSAID remaining in the skin. The concentration reached a steady state at 4e6 h after the application of each active ingredient or nanoparticle formulation. The quantity remaining in the skin was larger for the nanoparticle Table 1 Changes in NSAID particle size in formulations of particle dispersions containing NSAIDs, 14 d after treatment.
Residual drug concentration in the skin
Material
Particle Size (mm) formulation of each NSAID compared with the active ingredient forms. The quantity remaining in the skin began to show a significant increase at 4 h (IMC), 2 h (KET), and 4 h (PXC) after the application of the nanoparticles.
Carrageenan-induced footpad edema model
Edema peaked at 3 h after carrageenan treatment, with an edema coverage of 66.3 ± 2.2%, evaluated by analysis of edema coverage calculated from the foot volume (Fig. 4) . In each NSAID group, edema coverage began to decrease significantly at 1 h post treatment with the active ingredient or nanoparticle formulation, compared with the untreated group and the drugfree vehicle treatment group; this efficacy persisted until 6 h after treatment. Comparing the NSAIDai formulations with the NSAIDnano analogues, showed that edema coverage began to decrease significantly 2 h after treatment with IMCnano or PXCnano, demonstrating the edema-suppression effects of these preparations. Following KET treatment, edema coverage began to show a significant decrease at 1 h post treatment using the nanoparticle, compared with treatment using the active ingredient form, thereby demonstrating the edema-suppression effects of KETnano. In addition, AUC analysis demonstrated that the AUC was significantly lower following treatment using the nanoparticle form of each NSAID compared with treatment using the bulk analog (Table 3) .
Adjuvant-induced arthritis model
When each test drug was administered for 7 d after the induction of arthritis, the IMC groups exhibited a significant suppression of foot swelling on the first day of treatment, compared with the untreated group and the drug-free vehicle treatment group. On the fifth and seventh day of treatment, IMCnano showed a significant suppression of foot swelling, compared with IMCai (Fig. 5a ). The KET groups showed a significant suppression of foot swelling on the third day of treatment, compared with the untreated and drug-free vehicle treatment groups. On the seventh day of treatment, KETnano showed a significant suppression of foot swelling, compared 16.4 ± 0.9** 0.9 ± 0.2* 9.0 ± 0.2** 0.2 ± 0.1 5.0 ± 3.8 1.3 ± 0.6 230.3 ± 29.4** Results are expressed as mean ± SE of the data from six experiments. *p<0.05, **p < 0.01 compared with the corresponding NSAIDai group (analysis of variance followed by unpaired Student'st-test).
Of the skin penetration parameters, the penetration rate per unit area (J), the drug penetration coefficient (Kp), the drug diffusion coefficient (D), the ointment-toskin partition coefficient (Km), and the penetration lag-time (Tlag) were calculated using the following equations and the cumulative dose-time course data. Cs denotes the concentration in the ointment (mg), and d indicates the skin thickness (mean, 0.368 mm). The J and Tlag were calculated from the linear part of the cumulative dose-time course data. In addition, the area under the cumulative dose-time curve (AUC) was calculated. Fig. 3 . The influence of particle size on the concentration of each NSAID remaining in the skin. Results are expressed as mean ± SE. Differences in the efficacy of each particle size preparation between the two groups were tested using an unpaired Student's t-test. *p<0.05, **p<0.01 compared with the corresponding NSAIDai group.
with KETai (Fig. 5b) . In the PXC evaluation, PXCnano showed a significant suppression of foot swelling on the first day of treatment, while PXCai showed a significant suppression of foot swelling on the fifth day of treatment; when each of these groups was compared with the untreated and drug-free vehicle treatment groups. Compared with PXCai, PXCnano showed significant suppression of foot swelling from the third day following the start of treatment (Fig. 5c ). The healing rates for 7 d following the start of the test drug treatment are shown in Table 4 . The rates were 40.3, 43.0 and 35.8% for IMCai, KETai and PXCai, respectively, while they were 53.0, 57.4 and 66.8% for IMCnano, KETnano and PXCnano, respectively. A comparison of the three nanoparticle preparations revealed a tendency for PXCnano to be more effective than the other nanoparticle preparations.
Discussion
The present study was designed to investigate the potential of ointments containing NSAID nanoparticles in terms of skin penetration, safety and anti-inflammatory activity. Nanoparticles are colloidal dispersion systems. Because they are thermodynamically unstable, it is difficult to maintain a dispersion of nanoparticles in water for a long period, and aggregation and sedimentation are likely to occur. 28, 29 The nanoformulations prepared were free of sedimentation at 14 d post preparation, and the particle size remained unchanged. The ointments containing NSAIDs were prepared to give resulting NSAID concentrations equivalent to those of commercially available NSAID products in Japan. In the in vitro skin penetration test, the cumulative penetration increased linearly for each NSAID ointment during the 24 h after application. The skin surface can be damaged by the application of several drugs, and drug penetration can increase as a result. 30 For each of the NSAID ointments prepared in this study, a primary skin test was conducted in rabbits (data not shown). Following the application of the active ingredient drug or nanoparticle, both untreated intact skin and damaged skin, showed no stimulus-induced reaction throughout the observation period. The present study revealed that NSAIDnano formulations enabled greater penetration of drug into the skin compared with NSAIDai. These results indicate differences in the skin penetration profiles of NSAIDai and NSAIDnano and suggest a higher local activity of NSAIDnano, compared with NSAIDai, when applied to the skin. The horny layer, the outermost layer of the skin, is the most prominent skin barrier, and the intercellular spaces in this layer are considered to have dimensions in the 50e100 nm range. Because the NSAIDnano formulations produced in this study had a particle size of 70e80 nm, it was assumed that percutaneous penetration of the nanoparticle formulations would be enhanced. To achieve systemic delivery of active ingredients applied to the skin, these ingredients must Fig. 4 . Time course of edema after topically applied NSAIDs in carrageenan-induced footpad inflammation in rats. Results are expressed as mean ± SE of the data from six animals.*p < 0.05, **p < 0.01 compared with the corresponding control group (analysis of variance followed by Dunnett's test). #p < 0.01 compared with the corresponding NSAIDai group (analysis of variance followed by unpaired Student's t-test). A Control, ⋄ Ointment base, B IMCai, C IMCnano, △ KETai, : KETnano, , PXCai, -PXCnano. penetrate the epidermis and enter blood vessels located in tissues below the dermis. In this study, because concentrations of residual drugs in the skin were higher for the nanoparticle formulations, an increase in their percutaneous permeability can reasonably be assumed. In the acute inflammation model, the edema coverage after treatment with each NSAIDnano formulation was significantly lower compared with those after treatment with each NSAIDai preparation. Carrageenan-induced footpad inflammation caused by the release of serotonin and histamine, arises during the first phase, while kinins and PGs are involved in the second phase.
31e33 NSAIDs suppress edema during both the first and second phases. The chronic model is also known to involve two inflammatory processes. Primary inflammation begins on the day following the injection of the adjuvant into the hindlimb. Secondary inflammation begins at 7 d after the adjuvant injection. 34, 35 The pathogenic processes and the histopathological features of the resulting lesions, are similar to those observed in human rheumatoid arthritis. 36, 37 Both NSAIDai and NSAIDnano suppressed foot swelling in a time-dependent manner. The healing rates at 7 d post treatment were significantly higher following treatment with each NSAIDnano preparation compared with the NSAIDai preparations. The concentrations of NSAIDnano required to suppress edema were much lower than those of the NSAIDai, indicating the potency of the NSAIDnano formulations. A comparison among the nanoparticle preparations revealed a tendency for PXCnano to be more effective than the other nanoparticle preparations. Regarding the effects of NSAIDs on acute inflammation; after the onset of carrageenan-induced inflammation, cyclooxygenase levels reportedly reach a plateau 3e5 h after administration of NSAIDs, therefore the mode of action of the test drugs appears to be inhibition of expressed cyclooxygenase. In contrast, because the immune system is involved in the pathogenic mechanisms underlying chronic inflammation, it was assumed that the test drugs exerted their effects through not only inhibition of cyclooxygenase, but also inhibition of leukocyte migration and plasma membrane stabilization. Thus, NSAIDs appear to be effective for not only acute, but also chronic inflammation because they have various modes of action. NSAIDnano preparations are expected to serve as percutaneously absorbable preparations with excellent efficacy for a variety of diseases and conditions. Considering that the skin penetration potential, the residual drug levels in the skin, and the efficacy at the inflamed site, were higher for NSAIDnano than for NSAIDai, the NSAIDnano formulations could potentially serve as the basis for new pharmaceutical products. Furthermore, the results from the current study suggest that NSAIDnano preparations can exert anti-inflammatory effects at lower drug concentrations than those currently used, and may enable longerlasting activity. These features could help to reduce healthcare expenditure.
However, products containing NSAIDnano might undergo changes in terms of pharmacokinetics and safety, and they would likely be required to undergo evaluations such as those currently required for new drugs before clinical use. The exact skin penetration mechanism of these formulations must be clarified, and further research into the development of appropriate ad ditives and formulations is needed. The NSAIDs used in this study have been investigated in conjunction with nanoparticles in other studies, 14,17,38e40 however the method of nanoparticle synthesis used here has the following Fig. 5 . Time course of edema after topically applied NSAIDs in adjuvant-induced arthritis in rats. Results are expressed as mean ± SE of the data from six animals. *p<0.05, **p<0.01 compared with the corresponding control group (analysis of variance followed by Dunnett's test). #p < 0.05, ##p < 0.01 compared with the corresponding NSAIDai group (analysis of variance followed by unpaired Student's t-test). A Control, ⋄ Ointment base, B IMCai, C IMCnano, △ KETai, : KETnano, , PXCai, -PXCnano. Results are expressed as mean ± SE of the data from six animals.
advantages over those described in previous reports: 1) No organic solvents were used in nanoparticle synthesis, and no stabilizer was added. 2) No specialized equipment was used, with the exception of a rotating and revolving crusher, which is easy to obtain.
3) The ointment formulation was prepared by dissolving the nanoparticles in a small amount of ethanol, followed by mixing with an ointment base, and contains few substances such as gels, polymers, and surfactants that are irritating to the skin. The preparation cost of the nanoparticles is therefore expected to be low, and basic safety considerations have been made. These nanoparticle NSAIDs could provide an effective and valid means of treatment, while avoiding undesirable adverse reactions. The utilization of nanoparticles may lead to the development of new pharmaceutical products for percutaneous use.
